Tailored Treatment of Colorectal Cancer: Surgical, Molecular, and Genetic Considerations [0.03%]
结直肠癌的个体化治疗：外科、分子和遗传学考量
Knut Magne Augestad,Marianne A Merok,Dejan Ignatovic
Knut Magne Augestad
Colorectal cancer (CRC) is a complex cancer disease, and approximately 40% of the surgically cured patients will experience cancer recurrence within 5 years. During recent years, research has shown that CRC treatment should be tailored to t...
Effects of Serum Leptin and Resistin Levels on Cancer Cachexia in Patients With Advanced-Stage Non-Small Cell Lung Cancer [0.03%]
人晚期非小细胞肺癌患者血清瘦素和抵抗素水平对癌症恶病质的影响
Gökcen Demiray,Serkan Değirmencioğlu,Erhan Uğurlu et al.
Gökcen Demiray et al.
Introduction: Cancer cachexia is one of the most frequent effects of malignancy, is often associated with poor prognosis, and may account for up to 20% of cancer deaths. The aim of our study was to evaluate the relationsh...
Juan Antonio González-Sánchez,Rebeca Vitón,Elena Collantes et al.
Juan Antonio González-Sánchez et al.
Squamous cell carcinoma (SCC) of the stomach is a rare entity. There are several theories regarding the development of this tumor, but its pathogenesis remains obscure. Fewer than 100 cases of primary SCC of the stomach have been published ...
Xiaolan Fang,Jeanny Aragon-Ching,Esther Una Cidon
Xiaolan Fang
A Partial Response to Reintroduced Chemotherapy in a Resistant Small Cell Lung Cancer Patient After Priming with RRx-001 [0.03%]
RRx-001预处理后复发的小细胞肺癌患者的化疗部分反应
Bryan Oronsky,Scott Caroen,Karen Zeman et al.
Bryan Oronsky et al.
As an exceedingly recalcitrant and highly aggressive tumor type without Food and Drug Administration-approved treatment or a known cure, the prognosis of recurrent extensive stage platinum-resistant/refractory small cell lung cancer (SCLC) ...
Role of Chemotherapy and Mechanisms of Resistance to Chemotherapy in Metastatic Castration-Resistant Prostate Cancer [0.03%]
转移性去势抵抗性前列腺癌的化疗作用及耐药机制
Vipin Lohiya,Jeanny B Aragon-Ching,Guru Sonpavde
Vipin Lohiya
Chemotherapy using the taxanes, docetaxel and cabazitaxel, remains an important therapeutic option in metastatic castration-resistant prostate cancer (CRPC). However, despite the survival benefits afforded by these agents, the survival incr...
Is Adherence to Imatinib Mesylate Treatment Among Patients with Chronic Myeloid Leukemia Associated with Better Clinical Outcomes in Qatar? [0.03%]
甲磺酸伊马替尼治疗慢性髓系白血病患者的依从性及其与卡塔尔患者临床结局之间的关系分析
Nader I Al-Dewik,Hisham M Morsi,Muthanna M Samara et al.
Nader I Al-Dewik et al.
Background: Despite the revolutionary success of introducing tyrosine kinase inhibitors (TKIs), such as imatinib mesylate (IM), for treating chronic myeloid leukemia (CML), a substantial proportion of patients' treatments...
Monitoring Metastasis and Cachexia in a Patient with Breast Cancer: A Case Study [0.03%]
一例乳腺癌转移和恶病质的病例报告
Nikita Consul,Xiaotao Guo,Courtney Coker et al.
Nikita Consul et al.
Cachexia, a wasting syndrome associated with advanced cancer and metastasis, is rarely documented in breast cancer patients. However, the incidence of cachexia in breast cancer is now thought to be largely underestimated. In our case report...
Age, Neurological Status MRC Scale, and Postoperative Morbidity are Prognostic Factors in Patients with Glioblastoma Treated by Chemoradiotherapy [0.03%]
年龄、神经系统状态MRC量表和术后并发症是接受化疗联合放疗的胶质母细胞瘤患者的预后因素
Clotilde Verlut,Guillaume Mouillet,Eloi Magnin et al.
Clotilde Verlut et al.
Introduction: Temozolomide and concomitant radiotherapy followed by temozolomide has been used as a standard therapy for the treatment of newly diagnosed glioblastoma multiform since 2005. A search for prognostic factors ...
Millena Prata Jammal,Agrimaldo Martins-Filho,Thales Parenti Silveira et al.
Millena Prata Jammal et al.
Introduction: Ovarian cancer has a high mortality and delayed diagnosis. Inflammation is a risk factor for ovarian cancer, and the inflammatory response is involved in almost all stages of tumor development. Immunohistoch...